BTAI
BioXcel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.07
−37.11%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 742.0K | 642.0K | 2.3M | 1.4M | 375.0K |
| Cost of Revenue | 406.0K | 164.0K | 2.1M | 1.3M | 20.0K |
| Gross Profit | 336.0K | 478.0K | 123.0K | 120.0K | 355.0K |
| Operating Expenses | |||||
| R&D Expense | 21.6M | 30.3M | 30.4M | 84.3M | 91.2M |
| SG&A Expense | 23.6M | 20.5M | 34.5M | 83.4M | 68.8M |
| General & Admin Expense | 16.2M | 20.1M | 33.1M | 63.5M | 55.8M |
| Selling & Marketing Expense | 200.0K | 407.0K | 1.4M | 19.9M | 13.0M |
| Other Expenses | (163.0K) | — | 2.4M | 4.2M | — |
| Total Operating Expenses | 45.0M | 50.7M | 67.4M | 171.9M | 160.0M |
| Cost and Expenses | 45.4M | 50.9M | 69.5M | 173.2M | 160.0M |
| Operating Income (EBIT) | (44.6M) | (50.3M) | (67.2M) | (171.8M) | (159.6M) |
| Non-Operating | |||||
| Interest Income | 899.0K | 1.1M | 2.6M | 5.6M | 2.5M |
| Interest Expense | 17.2M | 17.0M | 15.1M | 13.3M | 8.2M |
| Net Interest Income | (16.3M) | (15.9M) | (12.5M) | (7.7M) | (5.7M) |
| Other Non-Op Income/Expense | (26.2M) | (19.6M) | 7.6M | (7.3M) | (6.1M) |
| Non-Operating Income (excl Interest) | 9.0M | 2.6M | (22.8M) | (6.0M) | (2.1M) |
| EBT (Pre-Tax Income) | (70.9M) | (69.9M) | (59.6M) | (179.1M) | (165.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (70.9M) | (69.9M) | (59.6M) | (179.1M) | (165.8M) |
| Earnings from Cont. Ops | (70.9M) | (69.9M) | (59.6M) | (179.1M) | (165.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (70.9M) | (69.9M) | (59.6M) | (179.1M) | (165.8M) |
| Per Share | |||||
| Basic EPS | ($5.46) | ($5.73) | ($23.51) | ($98.35) | ($94.67) |
| Diluted EPS | ($5.46) | ($5.73) | ($23.51) | ($98.35) | ($94.67) |
| Revenue Per Share | $0.06 | $0.05 | $0.89 | $0.76 | $0.21 |
| Shares | |||||
| Basic Shares Outstanding | 12.2M | 12.2M | 2.5M | 1.8M | 1.8M |
| Diluted Shares Outstanding | 12.2M | 12.2M | 2.5M | 1.8M | 1.8M |
| Profitability Metrics | |||||
| EBITDA | (53.4M) | (52.6M) | (44.2M) | (165.4M) | (157.2M) |
| D&A | 225.0K | 300.0K | 309.0K | 318.0K | 327.0K |
| EBIT | (53.6M) | (52.9M) | (44.5M) | (165.7M) | (157.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026